The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) on April 16, 2021. This approval pertains to an efficacy supplement, indicating an expansion of the drug's approved uses.
Background
Nivolumab, marketed as Opdivo, is a well-established therapeutic agent. This supplemental approval from the FDA specifically addresses an efficacy component, suggesting an expansion or refinement of its demonstrated effectiveness.
What this means
The FDA's approval of this supplemental efficacy application for Opdivo (nivolumab) means that the drug's label has been updated to reflect new or expanded evidence of its effectiveness. While the specific new indication or patient population is not detailed in the provided information, such approvals typically allow clinicians to prescribe Opdivo for additional conditions or in new treatment settings where its efficacy has been demonstrated. This expands the potential therapeutic options for patients who may benefit from nivolumab.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 125554 S-91, a supplemental efficacy application for Opdivo (nivolumab), was recorded on April 16, 2021, and is accessible via accessdata.fda.gov.